This article was downloaded by: [New York University] On: 27 July 2015, At: 13:37 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: 5 Howick Place, London, SW1P 1WG
Adipocyte Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/kadi20
Erythropoietin and obesity-induced white adipose tissue inflammation: redefining the boundaries of the immunometabolism territory Mawadda Alnaeeli
ab
& Constance Tom Noguchi
c
a
Department of Biological Sciences; Ohio University; Zanesville, OH USA
b
Diabetes Institute at Ohio University; Athens, OH USA
c
Molecular Medicine Branch; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; Bethesda, MD USA Accepted author version posted online: 15 Dec 2014.Published online: 07 Jan 2015.
Click for updates To cite this article: Mawadda Alnaeeli & Constance Tom Noguchi (2015) Erythropoietin and obesity-induced white adipose tissue inflammation: redefining the boundaries of the immunometabolism territory, Adipocyte, 4:2, 153-157, DOI: 10.4161/21623945.2014.978654 To link to this article: http://dx.doi.org/10.4161/21623945.2014.978654
PLEASE SCROLL DOWN FOR ARTICLE Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content. This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http:// www.tandfonline.com/page/terms-and-conditions
COMMENTARY Adipocyte 4:2, 153--157; April/May/June 2015; © 2015 Taylor & Francis Group, LLC
Erythropoietin and obesity-induced white adipose tissue inflammation: redefining the boundaries of the immunometabolism territory Mawadda Alnaeeli1,2 and Constance Tom Noguchi3,* 1
Department of Biological Sciences; Ohio University; Zanesville, OH USA; 2Diabetes Institute at Ohio University; Athens, OH USA; 3Molecular Medicine Branch;
National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; Bethesda, MD USA
Downloaded by [New York University] at 13:37 27 July 2015
T
Keywords: adipocytes, chemokines, chemokines, cytokines, erythropoietin, erythropoietin receptor, immunometabolism, macrophages, obesity-induced inflammation, white adipose tissue *Correspondence to: Constance Tom Noguchi; Email: [email protected] Submitted: 07/07/2014 Revised: 09/29/2014 Accepted: 10/15/2014 http://dx.doi.org/10.4161/21623945.2014.978654 Commentary to: Alnaeeli M, Raaka B, Gavrilova O, Teng R, Chanturiya T, Noguchi CT. Erythropoietin signaling: a novel regulator of white adipose tissue inflammation during diet-induced obesity. Diabetes 2014; 63(7):2415-31; PMID:24647735; http://dx.doi.org/10.2337/db13-0883
www.tandfonline.com
he adipose tissue represents a critical and predominant site for the interaction between metabolic and inflammatory responses during health and disease. In the white adipose tissue microenvironment, macrophages/adipocytes cross-talk have been shown to influence the metabolic and inflammatory states of both cell types, and contribute to the development of systemic insulin resistance during obesity. Indeed, the existence of paracrine loops between mature adipocytes and macrophages, especially during obesityinduced stress, involving the release of, and response to, an array of cytokines and regulatory factors, have been extensively studied using several in vitro and in vivo model systems. Published evidence together with recent observations, brought to light the unexpected role of erythropoietin and its receptor in the regulation of white adipose tissue mass, energy homeostasis, and inflammation as demonstrated by erythropoietin effects on adipocyte development and metabolic profile, and macrophage infiltration, cytokine responses, and activation state during diet-induced obesity. In this commentary, we discuss the newly added elements and perspectives to our understanding of the erythropoietin/ erythropoietin-receptor axis as a regulator of obesity-induced white adipose tissue inflammation, providing insight into its effects on cytokine responses of macrophages and adipocytes, and possible links to glucose metabolism and insulin resistance.
Obesity-induced insulin resistance is a risk factor for type 2 diabetes. Key to the Adipocyte
development of obesity-induced insulin resistance and a hallmark of the metabolic stress are the ongoing chronic inflammation, both systemically and locally in the white adipose tissue.1-4 The latter is largely mediated by macrophages (ML), whose responses, activation states, and their interactions with adipocytes strongly influence the inflammatory basis of metabolic deterioration. Erythropoietin (EPO), discovered for its indispensable role during erythropoiesis, is a glycoprotein hormone primarily produced in the adult kidneys, and its recombinant form is clinically used for the treatment of anemia in chronic kidney disease including type 2 diabetes patients undergoing renal dialysis.5 EPO expression is induced in response to hypoxia, via the activation of hypoxia inducible factor pathway.6 EPO exerts its function via its receptor EPO-R, a member of the class I cytokine receptor family. In addition to its indispensible role during erythropoiesis, other biological activities for EPO have also been reported.7,8 Beyond erythropoiesis, EPO increases blood flow and oxygen delivery through its effects on the vascular endothelium.9,10 Moreover, EPO has anti-apoptotic and tissue protective effects leading to reduced ML infiltration and inhibited pro-inflammatory cytokines expression e.g. TNF-a in experimental models of multiple sclerosis and ischemia-induced injury.11,12 In the context of obesity, we and others showed that EPO improved glucose intolerance and decreased body weight and fat mass accumulation.13–16 EPO-R is highly expressed in white adipose tissue by both adipocytes and stromal vascular fraction, where its signaling inhibit adipogenesis, 153
Downloaded by [New York University] at 13:37 27 July 2015
and regulate body weight and fat mass.15,16 EPO-R is also highly expressed in the hypothalamus where its signaling is involved in regulating physical activity and food intake.15,16 Using differentiated 3T3-L1 cell line as an in vitro model system to study adipocytes, it was recently proposed that EPO improves insulin resistance, up-regulates glucose uptake, increases adiponectin, and reduces leptin and TNF-a levels via direct signaling in adipocytes.17 In addition, using mice with adipocyte-specific deletion of EPO receptor, we reported that adipocyte-specific blockade of EPO/EPOR signaling results in obesity, and decreased glucose tolerance and insulin sensitivity when fed high fat diet.18 Our findings demonstrated that EPO increased oxidative metabolism, fatty acid oxidation, and key metabolic genes in adipocytes, and in white adipose tissue of obese wildtype mice. The increased metabolic activity by EPO was found to be associated with induction of brown fat-like features in white adipocytes, as demonstrated by increases in brown fat gene expression, mitochondrial content, and uncoupled respiration.18 Although this remains controversial, as conflicting evidence exists,19 likely due to differences in the genetic background of the mice used in these studies, our findings strongly suggest that EPO may be a contributing player during adipose energy homeostasis in conjunction with other metabolism co-regulators, providing a potential therapeutic strategy to protect against obesity and metabolic disorders.18 Collectively, these observations summarized above, prompted us to explore additional non-erythroid effects for EPO in the context of adipose tissue microenvironment. Considering the previously reported links between obesity-induced white adipose tissue inflammation and insulin resistance,1–4 the fact that the antiinflammatory effects driving EPO-mediated regulation of insulin resistance, and the underlying mechanisms downstream of EPO-R signaling in white adipose tissue ML remained unknown, we explored EPO/EPO-R contribution to the regulation of obesity-induced adipose tissue inflammation. Using the model of dietinduced obesity in C57BL/6 mice, we
154
found exogenous and endogenous EPO to directly target ML activity and responses, inhibit white adipose tissue inflammation, and attenuate insulin resistance.20 Our main findings demonstrated that: (i) EPO treatment has an anti-inflammatory effect on white adipose tissue macrophage population during diet-induced obesity in addition to its associated metabolic improvements on glucose tolerance and insulin sensitivity in vivo; (ii) in this model of obesity, EPO treatment reduced pro-inflammatory [M1-like] and increased anti-inflammatory [M2-like] ML in visceral white adipose tissue depot; in addition (iii) EPO decreased circulating inflammatory monocytes; and lastly (iv) we found the anti-inflammatory effects of EPO to be driven, at least in part, by direct EPO-R response in ML via Stat3 activation.20 It is noteworthy that EPO effects on M2 but not M1 ML required interleukin-4 receptor/Stat6 axis, and were not restricted to treatment with exogenous high dose EPO (1000U/kg), but also include endogenous physiological EPO levels as demonstrated by the series of studies conducted using DEpoR mouse model where EPO-R expression is restricted to erythroid cells. These findings have collectively identified EPO/EPO-R signaling as a novel regulator of white adipose tissue inflammation and ML polarization, and linked such effects to improved glucose metabolism during diet-induced obesity. This is consistent with the critical role of ML in the development of insulin resistance and glucose intolerance during obesity-induced inflammation.1–4 Previous reports in the literature showed that EPO can (i) inhibit macrophage inflammatory response in the gut and systemically,21 and (ii) promote cholesterol efflux in lipid laden ML (i.e. foam cells).22 In the white adipose tissue during diet-induced obesity, we show that EPO/EPO-R signaling regulates inflammation and macrophage responses.20 We were surprised to find that EPO promotes the expansion of the white adipose tissue M2-like macrophage population, as a result of increased IL-4 levels that drive their proliferation in situ, where the antiinflammatory effects of EPO emerged prior to any detectable changes in body weight or composition.20
Adipocyte
Obesity-induced inflammation and immune cell infiltration result in elevated levels of cytokines and chemokines such as TNF-a and CCL2, both systemically and locally in WAT, where cells of the stromal vascular fraction including ML, are known to be the main producing source, particularly in visceral fat depots.2,23–26 Interestingly, ML infiltration to WAT has been shown to require, and kinetically follow CD8C T lymphocytes recruitment.27 During inflammation, cytokines such as TNF-a can block insulin receptor signaling via mechanisms that range from reduced activity of Akt, JNK-mediated activation of insulin receptor substrate serine phosphorylation, to the direct degradation of insulin receptor substrate.28,29 Not surprisingly, the inhibition of ML infiltration and monocytes recruitment to WAT by means of blocking the expression and/or signaling of adhesion molecules such as osteopontin, MGL-1 and b4 integrin or inflammatory chemokines namely CCL2 (MCP-1), have been reported to ameliorate insulin resistance by blunting the inflammatory response.30–33 Whereas, their increased infiltration to WAT, accomplished by targeted tissue specific CCL2 over-expression, resulted in insulin resistance and glucose intolerance.34 As previously indicated, signaling of certain inflammatory mediators such as TNF-a has been adversely implicated in the impairment of glucose metabolism by interference with insulin receptor signaling.2,35 Considering our observations that ML are EPO responsive, and the key contribution of ML to the development of obesity-induced insulin resistance and glucose intolerance,1–4 we propose that a direct contribution of their EPO/EPO-R signaling is one of the pathways driving the observed improvement of glucose metabolism, possibly via the inhibition of white adipose tissue inflammation. One key piece of evidence in support of this is the fact that EPO/EPO-R signaling down-regulates TNF-a and CCL-2 protein levels, in addition to down-regulating the gene expression of Ccl1, Ccl2, Ccl3 and Ccl22 in stromal vascular fraction,20 thus linking the positive effects of EPO/ EPO-R on systemic insulin sensitivity and glucose tolerance to reduced inflammatory
Volume 4 Issue 2
Downloaded by [New York University] at 13:37 27 July 2015
Figure 1. Male C57BL/6 wild type mice with obesity induced by HFD feeding for 12 wks beginning at 6–8 weeks of age, were treated with (black bar) or without (gray bar) EPO (1000U/kg) every 48 hr during the final 2 weeks of the study. Lean mice treated with saline (LeanCSaline; open bar) were used as negative controls. Adipocytes were separated from stromal vascular fraction cells using perigonadal fat, and ML were purified by FACS from stromal vascular fraction cells using F4/80. Expression of inflammatory cytokine and chemokine genes in adipocytes (A), and ML (B), were analyzed by qRT-PCR; expression levels are normalized to b-actin, and fold change in expression are relative to negative control LeanCSaline. mRNA levels were quantified. Data represent observations from 3 independent experiments with similar results plotted as meanCSEM for nD4 per group, where statistical significance is *P < 0 .05.
response. These studies were performed using mouse inflammatory cytokines and receptors RT2 profiler PCR array (Qiagen), which profiles the expression of 84 key genes mediating the inflammatory response. The exact molecular networks driving this link, such as the role of JAK/ STAT pathway and Akt activation downstream of EPO-R signaling, including the possibility of insulin sensitivity regulation
www.tandfonline.com
by directly affecting signaling downstream of insulin receptor require further studies. As part of our efforts to delineate the effects of EPO/EPO-R signaling on the ongoing chronic inflammation in the white adipose tissue inflammation microenvironment, we characterized the effect of in vivo EPO treatment on cytokine/ chemokine gene expression profiles in ML versus adipocytes sorted from the
Adipocyte
visceral fat of obese animals, using mouse inflammatory cytokines and receptors RT2 profiler PCR array, ex vivo after treatment. As expected, EPO treatment of obese animals resulted in reduced gene expression of Ccl1, Ccl5, Ccl22, and Tnfa, while increasing the expression of Il10 in their white adipose tissue ML when compared to saline treated controls (Fig. 1A). In contrast, the effect of EPO treatment on the cytokine/chemokine gene expression of adipocytes was limited, at the tested time points, with marked effects only on Ccl22 and Il1b (Fig. 1B). These findings further underscore the inhibitory effects for EPO on obesityinduced inflammation, especially on ML, in the white adipose tissue microenvironment. Mechanisms other than anti-inflammatory activity during EPO-mediated regulation of glucose metabolism in dietinduced obesity also contribute to EPO response, particularly in skeletal muscle. It has been suggested that a shift to increased fat oxidation in muscle contributes to the observed normalization of glucose sensitivity with EPO.13 In the white adipose tissue, we found that EPO-mediated improvement of glucose metabolism was associated with increased oxidative metabolism, fatty acid oxidation, and key metabolic genes in adipocytes in vitro and in vivo.18 Lastly, the possibility that EPO can directly influence insulin production by pancreatic b-islet cells, or directly regulate insulin receptor signaling is also of interest, particularly in light of the observed negative correlation between serum insulin levels and EPO/EPO-R signaling.20 However, b-cell function as measured by insulin production is not affected by EPO in experimental models of type 1 and 2 diabetes,36 which argues against the involvement for EPO signaling in regulation of b-cell function.
Summary and Conclusion Herein we propose a model to summarize the effects of EPO/EPO-R signaling on the adipose tissue microenvironment during obesity-induced inflammation (Fig. 2), providing insight into the role of EPO/EPO-R axis in the regulation of ML
155
Downloaded by [New York University] at 13:37 27 July 2015
subsets, and cytokine/chemokine responses in ML vs. adipocytes (Fig. 1 and 2). Our findings extend the non-erythroid activity of EPO to encompass effects on macrophage infiltration, subset composition, and cytokine/chemokine responses in white fat, with potential implications in clinical practice. Although, our understanding of the exact molecular mechanisms driving the contribution of adipocytes and/or ML responses to EPO at the metabolic and inflammatory interface, in particular the connection between inflammation regulation and insulin resistance, remains at its infancy, the new roles for EPO and EPO-R in regulating inflammation and metabolism in the white adipose tissue microenvironment surely redefines the boundaries of EPO biology within the territory of immunometabolism. Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed. Acknowledgments
This work was supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (ZIA/ DK025102).
Figure 2. Proposed model for EPO/EPO-R signaling in the adipose tissue microenvironment during obesity-induced inflammation summarizing known EPO effects on i) M1 versus M2-like ML populations, and ii) cytokine/chemokine gene expression profiles in ML vs. adipocytes.
References 1. Zeyda M, Stulnig T: Obesity, inflammation and insulin resistance-a mini-review. Gerontology 2009; 55: 37986; PMID:19365105; http://dx.doi.org/10.1159/ 000212758 2. Olefsky JM, Glass CK: Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010; 72:21946; PMID:20148674; http://dx.doi.org/10.1146/ annurev-physiol-021909-135846
156
3. Lumeng CN, Saltiel AR: Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121 (6): 2111-7; PMID:21633179; http://dx.doi.org/ 10.1172/JCI57132 4. Han JM and Levings MK. Immune regulation in obesity-associated adipose inflammation. J Immunol 2013; 191(2):527-32; PMID:23825387; http://dx.doi.org/ 10.4049/jimmunol.1301035 5. Schneider A, Schneider MP, Scharnagl H, Jardine AG, Wanner C, Drechsler C. Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes.
Adipocyte
BMC Nephrol 2013; 14: 67; PMID:23521816; http:// dx.doi.org/10.1186/1471-2369-14-67 6. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol, 1992; 12: 5447-54 7. Noguchi CT, Wang L, Rogers HM, Teng R, Jia Y. Survival and proliferation roles of erythropoietin beyond erythroid lineage. Expert Rev Mol Med 2008; 10:e36; PMID:19040789; http://dx.doi.org/ 10.1017/S1462399408000860
Volume 4 Issue 2
Downloaded by [New York University] at 13:37 27 July 2015
8. Zhang Y, Wang L, Dey S, Alnaeeli M, Suresh S, Rogers H, Teng R, Noguchi CT. Erythropoietin action in stress response, tissue maintenance and metabolism. Int J Mol Sci 2014; 15(6):10296-333; PMID:24918289; http://dx.doi.org/10.3390/ijms150610296 9. Kertesz N, Wu J, Chen TH, Sucov HM, Wu H. The role of erythropoietin in regulating angiogenesis. Dev Biol 2004; 276: 101-10; PMID:15531367; http://dx. doi.org/10.1016/j.ydbio.2004.08.025 10. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004; 104(7): 2073-80; PMID:15205261; http://dx.doi.org/10.1182/ blood-2004-02-0744 11. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198:971-5; PMID:12975460; http://dx.doi.org/ 10.1084/jem.20021067 12. Yuan R, Maeda Y, Li W, Lu W, Cook S, Dowling P. Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE. PLoS One 2008; 3:e1924; PMID:18382691; http://dx.doi.org/10.1371/journal.pone.0001924 13. Hojman P, Brolin C, Gissel H, Brandt C, Zerahn B, Pedersen BK, Gehl J. Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS One 2009; 4 (6):e5894; PMID:19521513; http://dx.doi.org/ 10.1371/journal.pone.0005894 14. Katz O, Stuible M, Golishevski N, Lifshitz L, Tremblay ML, Gassmann M, Mittelman M, Neumann D. Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. J Endocrinol 2010; 205(1):87-95; PMID:20061512; http://dx.doi.org/10.1677/JOE-09-0425 15. Foskett A, Alnaeeli M, Wang L, Teng R, Noguchi CT. The effects of erythropoietin dose titration during highfat diet-induced obesity. J Biomed Biotechnol 2011; 2011:373781; PMID:21541227 16. Teng R, Gavrilova O, Suzuki N, Chanturiya T, Schimel D, Hugendubler L, Mammen S, Yver DR, Cushman SW, Mueller E, et al. Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. Nat Commun 2011; 2:520; PMID:22044999 17. Pan Y, Shu JL, Gu HF, Zhou DC, Liu XL, Qiao QY, Fu SK, Gao FH, Jin HM. Erythropoietin improves insulin resistance via the regulation of its receptor-mediated signaling pathways in 3T3L1 adipocytes. Mol Cell Endocrinol 2013; 10; 367(1-2):116-23; PMID:23313788; http:// dx.doi.org/10.1016/j.mce.2012.12.027
www.tandfonline.com
18. Wang L, Teng R, Di L, Rogers H, Wu H, Kopp JB, Noguchi CT. PPARa and Sirt1 mediate erythropoietin action in increasing metabolic activity and browning of white adipocytes to protect against obesity and metabolic disorders. Diabetes 2013; 62(12):4122-31; PMID:23990359; http://dx.doi.org/10.2337/db13-0518 19. Luk CT, Shi SY, Choi D, Cai EP, Schroer SA, Woo M. In vivo knockdown of adipocyte erythropoietin receptor does not alter glucose or energy homeostasis. Endocrinology 2013; 154(10):3652-9; PMID:23885016; http://dx.doi.org/10.1210/en.2013-1113 20. Alnaeeli M, Raaka BM, Gavrilova O, Teng R, Chanturiya T, Noguchi CT. Erythropoietin signaling: A novel regulator of white adipose tissue inflammation during dietinduced obesity. Diabetes 2014; 63(7):2415-31; PMID:24647735; http://dx.doi.org/10.2337/db13-0883 21. Nairz M, Schroll A, Moschen AR, Sonnweber T, Theurl M, Theurl I, Taub N, Jamnig C, Neurauter D, Huber LA, et al. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-kB-inducible immune pathways. Immunity 2011; 34(1):61-74; PMID:21256055; http://dx. doi.org/10.1016/j.immuni.2011.01.002 22. Lu KY, Ching LC, Su KH, Yu YB, Kou YR, Hsiao SH, Huang YC, Chen CY, Cheng LC, Pan CC, et al. Erythropoietin suppresses the formation of macrophage foam cells: role of liver X receptor alpha. Circulation 2010; 121(16): 1828-37; PMID:20385932; http://dx.doi. org/10.1161/CIRCULATIONAHA.109.876839 23. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Speigelman BM. Increased adipose tissue expression of tumor necrosis factor- in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-15; PMID:7738205; http:// dx.doi.org/10.1172/JCI117936 24. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808; PMID:14679176; http:// dx.doi.org/10.1172/JCI200319246 25. Xu H, Banres GT, Yang Q, Tan G, Yan D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830; PMID:14679177; http://dx. doi.org/10.1172/JCI200319451 26. Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 2008; 14: 1225-30; PMID:18473870; http://dx.doi.org/ 10.2174/138161208784246153 27. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, Otsu M, Hara K, Ueki K, Sugiura S, et al. CD8C effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity.
Adipocyte
28.
29.
30.
31.
32.
33.
34.
35.
36.
Nat Med 2009; 15(8):914-20; PMID:19633658; http://dx.doi.org/10.1038/nm.1964 Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interaction with the insulin receptor and inhibits insulin action. J Biol Chem 2002; 277: 1531-7; PMID:11606564; http://dx.doi.org/10.1074/ jbc.M101521200 Shoelson, SE, Lee J, Goldine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-108; PMID:16823477; http://dx.doi.org/10.1172/JCI29069 Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance and hepatic steatosis in obesity. J Clin Invest 2006; 116(6):1494-505; PMID:16691291; http://dx.doi.org/10.1172/JCI26498 Feral CC, Neels JG, Kummer C, Slepak M, Olefsky JM, Ginsberg MH. Blockade of 4 integrin signaling ameliorates the metabolic consequences of high-fat diet-induced obesity. Diabetes 2008; 57: 1842-51; PMID:18426864; http://dx.doi.org/10.2337/db07-1751 Westcott DJ, Delproposto JB, Geletka LM, Wang T, Singer K, Saltiel AR, Lumeng CN. MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7/4hi monocytes in obesity. J Exp Med 2009; 206(13):3143-56; PMID:19995956; http://dx. doi.org/10.1084/jem.20091333 Kiefer FW, Zeyda M, Gollinger K, Pfau B, Neuhofer A, Weichhart T, S€aemann MD, Geyeregger R, Schlederer M, Kenner L, et al. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 2010; 59(4):935-46; PMID:20107108; http://dx.doi.org/10.2337/db09-0404 Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, Ohtsuka-Kowatari N, Kumagai, K, Sakamoto K, Kobayashi M. et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006; 281(36):26602-14; PMID:16809344; http://dx.doi.org/10.1074/jbc.M601284200 Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007; 56(1):16-23; PMID:17192460; http:// dx.doi.org/10.2337/db06-1076 Choi D, Schroer SA, Lu SY, Wang L, Wu X, Liu Y, Zhang Y, Gaisano HY, Wagner KU, Wu H, et al. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med 2010; 207:2831-42; PMID:21149549; http://dx.doi.org/ 10.1084/jem.20100665
157
Adipocyte Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/kadi20
Erythropoietin and obesity-induced white adipose tissue inflammation: redefining the boundaries of the immunometabolism territory Mawadda Alnaeeli
ab
& Constance Tom Noguchi
c
a
Department of Biological Sciences; Ohio University; Zanesville, OH USA
b
Diabetes Institute at Ohio University; Athens, OH USA
c
Molecular Medicine Branch; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; Bethesda, MD USA Accepted author version posted online: 15 Dec 2014.Published online: 07 Jan 2015.
Click for updates To cite this article: Mawadda Alnaeeli & Constance Tom Noguchi (2015) Erythropoietin and obesity-induced white adipose tissue inflammation: redefining the boundaries of the immunometabolism territory, Adipocyte, 4:2, 153-157, DOI: 10.4161/21623945.2014.978654 To link to this article: http://dx.doi.org/10.4161/21623945.2014.978654
PLEASE SCROLL DOWN FOR ARTICLE Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content. This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http:// www.tandfonline.com/page/terms-and-conditions
COMMENTARY Adipocyte 4:2, 153--157; April/May/June 2015; © 2015 Taylor & Francis Group, LLC
Erythropoietin and obesity-induced white adipose tissue inflammation: redefining the boundaries of the immunometabolism territory Mawadda Alnaeeli1,2 and Constance Tom Noguchi3,* 1
Department of Biological Sciences; Ohio University; Zanesville, OH USA; 2Diabetes Institute at Ohio University; Athens, OH USA; 3Molecular Medicine Branch;
National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; Bethesda, MD USA
Downloaded by [New York University] at 13:37 27 July 2015
T
Keywords: adipocytes, chemokines, chemokines, cytokines, erythropoietin, erythropoietin receptor, immunometabolism, macrophages, obesity-induced inflammation, white adipose tissue *Correspondence to: Constance Tom Noguchi; Email: [email protected] Submitted: 07/07/2014 Revised: 09/29/2014 Accepted: 10/15/2014 http://dx.doi.org/10.4161/21623945.2014.978654 Commentary to: Alnaeeli M, Raaka B, Gavrilova O, Teng R, Chanturiya T, Noguchi CT. Erythropoietin signaling: a novel regulator of white adipose tissue inflammation during diet-induced obesity. Diabetes 2014; 63(7):2415-31; PMID:24647735; http://dx.doi.org/10.2337/db13-0883
www.tandfonline.com
he adipose tissue represents a critical and predominant site for the interaction between metabolic and inflammatory responses during health and disease. In the white adipose tissue microenvironment, macrophages/adipocytes cross-talk have been shown to influence the metabolic and inflammatory states of both cell types, and contribute to the development of systemic insulin resistance during obesity. Indeed, the existence of paracrine loops between mature adipocytes and macrophages, especially during obesityinduced stress, involving the release of, and response to, an array of cytokines and regulatory factors, have been extensively studied using several in vitro and in vivo model systems. Published evidence together with recent observations, brought to light the unexpected role of erythropoietin and its receptor in the regulation of white adipose tissue mass, energy homeostasis, and inflammation as demonstrated by erythropoietin effects on adipocyte development and metabolic profile, and macrophage infiltration, cytokine responses, and activation state during diet-induced obesity. In this commentary, we discuss the newly added elements and perspectives to our understanding of the erythropoietin/ erythropoietin-receptor axis as a regulator of obesity-induced white adipose tissue inflammation, providing insight into its effects on cytokine responses of macrophages and adipocytes, and possible links to glucose metabolism and insulin resistance.
Obesity-induced insulin resistance is a risk factor for type 2 diabetes. Key to the Adipocyte
development of obesity-induced insulin resistance and a hallmark of the metabolic stress are the ongoing chronic inflammation, both systemically and locally in the white adipose tissue.1-4 The latter is largely mediated by macrophages (ML), whose responses, activation states, and their interactions with adipocytes strongly influence the inflammatory basis of metabolic deterioration. Erythropoietin (EPO), discovered for its indispensable role during erythropoiesis, is a glycoprotein hormone primarily produced in the adult kidneys, and its recombinant form is clinically used for the treatment of anemia in chronic kidney disease including type 2 diabetes patients undergoing renal dialysis.5 EPO expression is induced in response to hypoxia, via the activation of hypoxia inducible factor pathway.6 EPO exerts its function via its receptor EPO-R, a member of the class I cytokine receptor family. In addition to its indispensible role during erythropoiesis, other biological activities for EPO have also been reported.7,8 Beyond erythropoiesis, EPO increases blood flow and oxygen delivery through its effects on the vascular endothelium.9,10 Moreover, EPO has anti-apoptotic and tissue protective effects leading to reduced ML infiltration and inhibited pro-inflammatory cytokines expression e.g. TNF-a in experimental models of multiple sclerosis and ischemia-induced injury.11,12 In the context of obesity, we and others showed that EPO improved glucose intolerance and decreased body weight and fat mass accumulation.13–16 EPO-R is highly expressed in white adipose tissue by both adipocytes and stromal vascular fraction, where its signaling inhibit adipogenesis, 153
Downloaded by [New York University] at 13:37 27 July 2015
and regulate body weight and fat mass.15,16 EPO-R is also highly expressed in the hypothalamus where its signaling is involved in regulating physical activity and food intake.15,16 Using differentiated 3T3-L1 cell line as an in vitro model system to study adipocytes, it was recently proposed that EPO improves insulin resistance, up-regulates glucose uptake, increases adiponectin, and reduces leptin and TNF-a levels via direct signaling in adipocytes.17 In addition, using mice with adipocyte-specific deletion of EPO receptor, we reported that adipocyte-specific blockade of EPO/EPOR signaling results in obesity, and decreased glucose tolerance and insulin sensitivity when fed high fat diet.18 Our findings demonstrated that EPO increased oxidative metabolism, fatty acid oxidation, and key metabolic genes in adipocytes, and in white adipose tissue of obese wildtype mice. The increased metabolic activity by EPO was found to be associated with induction of brown fat-like features in white adipocytes, as demonstrated by increases in brown fat gene expression, mitochondrial content, and uncoupled respiration.18 Although this remains controversial, as conflicting evidence exists,19 likely due to differences in the genetic background of the mice used in these studies, our findings strongly suggest that EPO may be a contributing player during adipose energy homeostasis in conjunction with other metabolism co-regulators, providing a potential therapeutic strategy to protect against obesity and metabolic disorders.18 Collectively, these observations summarized above, prompted us to explore additional non-erythroid effects for EPO in the context of adipose tissue microenvironment. Considering the previously reported links between obesity-induced white adipose tissue inflammation and insulin resistance,1–4 the fact that the antiinflammatory effects driving EPO-mediated regulation of insulin resistance, and the underlying mechanisms downstream of EPO-R signaling in white adipose tissue ML remained unknown, we explored EPO/EPO-R contribution to the regulation of obesity-induced adipose tissue inflammation. Using the model of dietinduced obesity in C57BL/6 mice, we
154
found exogenous and endogenous EPO to directly target ML activity and responses, inhibit white adipose tissue inflammation, and attenuate insulin resistance.20 Our main findings demonstrated that: (i) EPO treatment has an anti-inflammatory effect on white adipose tissue macrophage population during diet-induced obesity in addition to its associated metabolic improvements on glucose tolerance and insulin sensitivity in vivo; (ii) in this model of obesity, EPO treatment reduced pro-inflammatory [M1-like] and increased anti-inflammatory [M2-like] ML in visceral white adipose tissue depot; in addition (iii) EPO decreased circulating inflammatory monocytes; and lastly (iv) we found the anti-inflammatory effects of EPO to be driven, at least in part, by direct EPO-R response in ML via Stat3 activation.20 It is noteworthy that EPO effects on M2 but not M1 ML required interleukin-4 receptor/Stat6 axis, and were not restricted to treatment with exogenous high dose EPO (1000U/kg), but also include endogenous physiological EPO levels as demonstrated by the series of studies conducted using DEpoR mouse model where EPO-R expression is restricted to erythroid cells. These findings have collectively identified EPO/EPO-R signaling as a novel regulator of white adipose tissue inflammation and ML polarization, and linked such effects to improved glucose metabolism during diet-induced obesity. This is consistent with the critical role of ML in the development of insulin resistance and glucose intolerance during obesity-induced inflammation.1–4 Previous reports in the literature showed that EPO can (i) inhibit macrophage inflammatory response in the gut and systemically,21 and (ii) promote cholesterol efflux in lipid laden ML (i.e. foam cells).22 In the white adipose tissue during diet-induced obesity, we show that EPO/EPO-R signaling regulates inflammation and macrophage responses.20 We were surprised to find that EPO promotes the expansion of the white adipose tissue M2-like macrophage population, as a result of increased IL-4 levels that drive their proliferation in situ, where the antiinflammatory effects of EPO emerged prior to any detectable changes in body weight or composition.20
Adipocyte
Obesity-induced inflammation and immune cell infiltration result in elevated levels of cytokines and chemokines such as TNF-a and CCL2, both systemically and locally in WAT, where cells of the stromal vascular fraction including ML, are known to be the main producing source, particularly in visceral fat depots.2,23–26 Interestingly, ML infiltration to WAT has been shown to require, and kinetically follow CD8C T lymphocytes recruitment.27 During inflammation, cytokines such as TNF-a can block insulin receptor signaling via mechanisms that range from reduced activity of Akt, JNK-mediated activation of insulin receptor substrate serine phosphorylation, to the direct degradation of insulin receptor substrate.28,29 Not surprisingly, the inhibition of ML infiltration and monocytes recruitment to WAT by means of blocking the expression and/or signaling of adhesion molecules such as osteopontin, MGL-1 and b4 integrin or inflammatory chemokines namely CCL2 (MCP-1), have been reported to ameliorate insulin resistance by blunting the inflammatory response.30–33 Whereas, their increased infiltration to WAT, accomplished by targeted tissue specific CCL2 over-expression, resulted in insulin resistance and glucose intolerance.34 As previously indicated, signaling of certain inflammatory mediators such as TNF-a has been adversely implicated in the impairment of glucose metabolism by interference with insulin receptor signaling.2,35 Considering our observations that ML are EPO responsive, and the key contribution of ML to the development of obesity-induced insulin resistance and glucose intolerance,1–4 we propose that a direct contribution of their EPO/EPO-R signaling is one of the pathways driving the observed improvement of glucose metabolism, possibly via the inhibition of white adipose tissue inflammation. One key piece of evidence in support of this is the fact that EPO/EPO-R signaling down-regulates TNF-a and CCL-2 protein levels, in addition to down-regulating the gene expression of Ccl1, Ccl2, Ccl3 and Ccl22 in stromal vascular fraction,20 thus linking the positive effects of EPO/ EPO-R on systemic insulin sensitivity and glucose tolerance to reduced inflammatory
Volume 4 Issue 2
Downloaded by [New York University] at 13:37 27 July 2015
Figure 1. Male C57BL/6 wild type mice with obesity induced by HFD feeding for 12 wks beginning at 6–8 weeks of age, were treated with (black bar) or without (gray bar) EPO (1000U/kg) every 48 hr during the final 2 weeks of the study. Lean mice treated with saline (LeanCSaline; open bar) were used as negative controls. Adipocytes were separated from stromal vascular fraction cells using perigonadal fat, and ML were purified by FACS from stromal vascular fraction cells using F4/80. Expression of inflammatory cytokine and chemokine genes in adipocytes (A), and ML (B), were analyzed by qRT-PCR; expression levels are normalized to b-actin, and fold change in expression are relative to negative control LeanCSaline. mRNA levels were quantified. Data represent observations from 3 independent experiments with similar results plotted as meanCSEM for nD4 per group, where statistical significance is *P < 0 .05.
response. These studies were performed using mouse inflammatory cytokines and receptors RT2 profiler PCR array (Qiagen), which profiles the expression of 84 key genes mediating the inflammatory response. The exact molecular networks driving this link, such as the role of JAK/ STAT pathway and Akt activation downstream of EPO-R signaling, including the possibility of insulin sensitivity regulation
www.tandfonline.com
by directly affecting signaling downstream of insulin receptor require further studies. As part of our efforts to delineate the effects of EPO/EPO-R signaling on the ongoing chronic inflammation in the white adipose tissue inflammation microenvironment, we characterized the effect of in vivo EPO treatment on cytokine/ chemokine gene expression profiles in ML versus adipocytes sorted from the
Adipocyte
visceral fat of obese animals, using mouse inflammatory cytokines and receptors RT2 profiler PCR array, ex vivo after treatment. As expected, EPO treatment of obese animals resulted in reduced gene expression of Ccl1, Ccl5, Ccl22, and Tnfa, while increasing the expression of Il10 in their white adipose tissue ML when compared to saline treated controls (Fig. 1A). In contrast, the effect of EPO treatment on the cytokine/chemokine gene expression of adipocytes was limited, at the tested time points, with marked effects only on Ccl22 and Il1b (Fig. 1B). These findings further underscore the inhibitory effects for EPO on obesityinduced inflammation, especially on ML, in the white adipose tissue microenvironment. Mechanisms other than anti-inflammatory activity during EPO-mediated regulation of glucose metabolism in dietinduced obesity also contribute to EPO response, particularly in skeletal muscle. It has been suggested that a shift to increased fat oxidation in muscle contributes to the observed normalization of glucose sensitivity with EPO.13 In the white adipose tissue, we found that EPO-mediated improvement of glucose metabolism was associated with increased oxidative metabolism, fatty acid oxidation, and key metabolic genes in adipocytes in vitro and in vivo.18 Lastly, the possibility that EPO can directly influence insulin production by pancreatic b-islet cells, or directly regulate insulin receptor signaling is also of interest, particularly in light of the observed negative correlation between serum insulin levels and EPO/EPO-R signaling.20 However, b-cell function as measured by insulin production is not affected by EPO in experimental models of type 1 and 2 diabetes,36 which argues against the involvement for EPO signaling in regulation of b-cell function.
Summary and Conclusion Herein we propose a model to summarize the effects of EPO/EPO-R signaling on the adipose tissue microenvironment during obesity-induced inflammation (Fig. 2), providing insight into the role of EPO/EPO-R axis in the regulation of ML
155
Downloaded by [New York University] at 13:37 27 July 2015
subsets, and cytokine/chemokine responses in ML vs. adipocytes (Fig. 1 and 2). Our findings extend the non-erythroid activity of EPO to encompass effects on macrophage infiltration, subset composition, and cytokine/chemokine responses in white fat, with potential implications in clinical practice. Although, our understanding of the exact molecular mechanisms driving the contribution of adipocytes and/or ML responses to EPO at the metabolic and inflammatory interface, in particular the connection between inflammation regulation and insulin resistance, remains at its infancy, the new roles for EPO and EPO-R in regulating inflammation and metabolism in the white adipose tissue microenvironment surely redefines the boundaries of EPO biology within the territory of immunometabolism. Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed. Acknowledgments
This work was supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (ZIA/ DK025102).
Figure 2. Proposed model for EPO/EPO-R signaling in the adipose tissue microenvironment during obesity-induced inflammation summarizing known EPO effects on i) M1 versus M2-like ML populations, and ii) cytokine/chemokine gene expression profiles in ML vs. adipocytes.
References 1. Zeyda M, Stulnig T: Obesity, inflammation and insulin resistance-a mini-review. Gerontology 2009; 55: 37986; PMID:19365105; http://dx.doi.org/10.1159/ 000212758 2. Olefsky JM, Glass CK: Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010; 72:21946; PMID:20148674; http://dx.doi.org/10.1146/ annurev-physiol-021909-135846
156
3. Lumeng CN, Saltiel AR: Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121 (6): 2111-7; PMID:21633179; http://dx.doi.org/ 10.1172/JCI57132 4. Han JM and Levings MK. Immune regulation in obesity-associated adipose inflammation. J Immunol 2013; 191(2):527-32; PMID:23825387; http://dx.doi.org/ 10.4049/jimmunol.1301035 5. Schneider A, Schneider MP, Scharnagl H, Jardine AG, Wanner C, Drechsler C. Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes.
Adipocyte
BMC Nephrol 2013; 14: 67; PMID:23521816; http:// dx.doi.org/10.1186/1471-2369-14-67 6. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol, 1992; 12: 5447-54 7. Noguchi CT, Wang L, Rogers HM, Teng R, Jia Y. Survival and proliferation roles of erythropoietin beyond erythroid lineage. Expert Rev Mol Med 2008; 10:e36; PMID:19040789; http://dx.doi.org/ 10.1017/S1462399408000860
Volume 4 Issue 2
Downloaded by [New York University] at 13:37 27 July 2015
8. Zhang Y, Wang L, Dey S, Alnaeeli M, Suresh S, Rogers H, Teng R, Noguchi CT. Erythropoietin action in stress response, tissue maintenance and metabolism. Int J Mol Sci 2014; 15(6):10296-333; PMID:24918289; http://dx.doi.org/10.3390/ijms150610296 9. Kertesz N, Wu J, Chen TH, Sucov HM, Wu H. The role of erythropoietin in regulating angiogenesis. Dev Biol 2004; 276: 101-10; PMID:15531367; http://dx. doi.org/10.1016/j.ydbio.2004.08.025 10. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004; 104(7): 2073-80; PMID:15205261; http://dx.doi.org/10.1182/ blood-2004-02-0744 11. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198:971-5; PMID:12975460; http://dx.doi.org/ 10.1084/jem.20021067 12. Yuan R, Maeda Y, Li W, Lu W, Cook S, Dowling P. Erythropoietin: a potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE. PLoS One 2008; 3:e1924; PMID:18382691; http://dx.doi.org/10.1371/journal.pone.0001924 13. Hojman P, Brolin C, Gissel H, Brandt C, Zerahn B, Pedersen BK, Gehl J. Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS One 2009; 4 (6):e5894; PMID:19521513; http://dx.doi.org/ 10.1371/journal.pone.0005894 14. Katz O, Stuible M, Golishevski N, Lifshitz L, Tremblay ML, Gassmann M, Mittelman M, Neumann D. Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. J Endocrinol 2010; 205(1):87-95; PMID:20061512; http://dx.doi.org/10.1677/JOE-09-0425 15. Foskett A, Alnaeeli M, Wang L, Teng R, Noguchi CT. The effects of erythropoietin dose titration during highfat diet-induced obesity. J Biomed Biotechnol 2011; 2011:373781; PMID:21541227 16. Teng R, Gavrilova O, Suzuki N, Chanturiya T, Schimel D, Hugendubler L, Mammen S, Yver DR, Cushman SW, Mueller E, et al. Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. Nat Commun 2011; 2:520; PMID:22044999 17. Pan Y, Shu JL, Gu HF, Zhou DC, Liu XL, Qiao QY, Fu SK, Gao FH, Jin HM. Erythropoietin improves insulin resistance via the regulation of its receptor-mediated signaling pathways in 3T3L1 adipocytes. Mol Cell Endocrinol 2013; 10; 367(1-2):116-23; PMID:23313788; http:// dx.doi.org/10.1016/j.mce.2012.12.027
www.tandfonline.com
18. Wang L, Teng R, Di L, Rogers H, Wu H, Kopp JB, Noguchi CT. PPARa and Sirt1 mediate erythropoietin action in increasing metabolic activity and browning of white adipocytes to protect against obesity and metabolic disorders. Diabetes 2013; 62(12):4122-31; PMID:23990359; http://dx.doi.org/10.2337/db13-0518 19. Luk CT, Shi SY, Choi D, Cai EP, Schroer SA, Woo M. In vivo knockdown of adipocyte erythropoietin receptor does not alter glucose or energy homeostasis. Endocrinology 2013; 154(10):3652-9; PMID:23885016; http://dx.doi.org/10.1210/en.2013-1113 20. Alnaeeli M, Raaka BM, Gavrilova O, Teng R, Chanturiya T, Noguchi CT. Erythropoietin signaling: A novel regulator of white adipose tissue inflammation during dietinduced obesity. Diabetes 2014; 63(7):2415-31; PMID:24647735; http://dx.doi.org/10.2337/db13-0883 21. Nairz M, Schroll A, Moschen AR, Sonnweber T, Theurl M, Theurl I, Taub N, Jamnig C, Neurauter D, Huber LA, et al. Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-kB-inducible immune pathways. Immunity 2011; 34(1):61-74; PMID:21256055; http://dx. doi.org/10.1016/j.immuni.2011.01.002 22. Lu KY, Ching LC, Su KH, Yu YB, Kou YR, Hsiao SH, Huang YC, Chen CY, Cheng LC, Pan CC, et al. Erythropoietin suppresses the formation of macrophage foam cells: role of liver X receptor alpha. Circulation 2010; 121(16): 1828-37; PMID:20385932; http://dx.doi. org/10.1161/CIRCULATIONAHA.109.876839 23. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Speigelman BM. Increased adipose tissue expression of tumor necrosis factor- in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-15; PMID:7738205; http:// dx.doi.org/10.1172/JCI117936 24. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808; PMID:14679176; http:// dx.doi.org/10.1172/JCI200319246 25. Xu H, Banres GT, Yang Q, Tan G, Yan D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830; PMID:14679177; http://dx. doi.org/10.1172/JCI200319451 26. Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 2008; 14: 1225-30; PMID:18473870; http://dx.doi.org/ 10.2174/138161208784246153 27. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, Otsu M, Hara K, Ueki K, Sugiura S, et al. CD8C effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity.
Adipocyte
28.
29.
30.
31.
32.
33.
34.
35.
36.
Nat Med 2009; 15(8):914-20; PMID:19633658; http://dx.doi.org/10.1038/nm.1964 Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interaction with the insulin receptor and inhibits insulin action. J Biol Chem 2002; 277: 1531-7; PMID:11606564; http://dx.doi.org/10.1074/ jbc.M101521200 Shoelson, SE, Lee J, Goldine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-108; PMID:16823477; http://dx.doi.org/10.1172/JCI29069 Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance and hepatic steatosis in obesity. J Clin Invest 2006; 116(6):1494-505; PMID:16691291; http://dx.doi.org/10.1172/JCI26498 Feral CC, Neels JG, Kummer C, Slepak M, Olefsky JM, Ginsberg MH. Blockade of 4 integrin signaling ameliorates the metabolic consequences of high-fat diet-induced obesity. Diabetes 2008; 57: 1842-51; PMID:18426864; http://dx.doi.org/10.2337/db07-1751 Westcott DJ, Delproposto JB, Geletka LM, Wang T, Singer K, Saltiel AR, Lumeng CN. MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7/4hi monocytes in obesity. J Exp Med 2009; 206(13):3143-56; PMID:19995956; http://dx. doi.org/10.1084/jem.20091333 Kiefer FW, Zeyda M, Gollinger K, Pfau B, Neuhofer A, Weichhart T, S€aemann MD, Geyeregger R, Schlederer M, Kenner L, et al. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 2010; 59(4):935-46; PMID:20107108; http://dx.doi.org/10.2337/db09-0404 Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, Ohtsuka-Kowatari N, Kumagai, K, Sakamoto K, Kobayashi M. et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006; 281(36):26602-14; PMID:16809344; http://dx.doi.org/10.1074/jbc.M601284200 Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007; 56(1):16-23; PMID:17192460; http:// dx.doi.org/10.2337/db06-1076 Choi D, Schroer SA, Lu SY, Wang L, Wu X, Liu Y, Zhang Y, Gaisano HY, Wagner KU, Wu H, et al. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med 2010; 207:2831-42; PMID:21149549; http://dx.doi.org/ 10.1084/jem.20100665
157
